Infant Bacterial Therapeutics AB (IFTBF)

Overview

Infant Bacterial Therapeutics AB (publ) operates within the pharmaceutical industry, focusing on the clinical stage development of drugs aimed at preventing or treating rare diseases that impact premature infants. The company, established in 2011 and headquartered in Stockholm, Sweden, dedicates its research and development efforts towards addressing conditions that are critical to the well-being of this vulnerable patient group. With a lead drug candidate designed to combat necrotizing enterocolitis and improve feeding tolerance in premature babies, Infant Bacterial Therapeutics AB is at the forefront of introducing innovative treatments for conditions that currently have limited therapeutic options.

Products and Services

• IBP-9414

  This lead drug candidate by Infant Bacterial Therapeutics AB is developed with the goal of preventing necrotizing enterocolitis (NEC), a serious and potentially fatal condition that affects the intestines of premature infants. Apart from its preventive role against NEC, IBP-9414 is also designed to enhance feeding tolerance in this patient population, aiming to significantly improve their overall health outcomes and survival rates.

• IBP-1016

  Targeting the treatment of gastroschisis, a rare and severe condition characterized by the intestines extending outside of the baby’s body through a hole beside the belly button, IBP-1016 represents Infant Bacterial Therapeutics AB's commitment to expanding its portfolio to include solutions for extremely rare pediatric diseases. This development underlines the company's dedication to addressing unmet medical needs within neonatology and pediatric surgery.